A 5% response rate with IMA402 monotherapy seems unlikely to turn heads.

The group touts a 72% ORR with SCIB1, but full Scope data have been pushed back into 2025.

Response rates in a key group shrink from 62% to 39% as the company blames a “clerical error”.

Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.

Moderna has also canned projects targeting KRAS and Ox40L/IL-23/IL-36γ.

An accelerated approval looks off the table, as the group’s first-line melanoma trial continues.

But the company hasn’t given details, and used a historical control rather than the study’s own control arm.

Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.